{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:58:27Z","timestamp":1786550307893,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41395-018-0053-4","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T14:13:29Z","timestamp":1524492809000},"page":"863-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elbasvir\/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2\/3 clinical Trials"],"prefix":"10.14309","volume":"113","author":[{"given":"Philippe J.","family":"Zamor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Ghalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velimir","family":"Luketic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natarajan","family":"Ravendhran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Balart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bach-Yen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliav","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Talwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Pearlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210309","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-17-20210309","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","article-title":"Jeffers LJ, the Virahep-C Study Group. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.","volume":"131","author":"Conjeevaram","year":"2006","journal-title":"Gastroenterology"},{"key":"R3-17-20210309","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/hep.28901","article-title":"The association between raceethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.","volume":"65","author":"Su","year":"2017","journal-title":"Hepatology"},{"key":"R4-17-20210309","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Saag M, for the ION-4 Investigators. et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1.","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-17-20210309","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hep.28334","article-title":"Safety and efficacy of ledipasvir -sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data.","volume":"63","author":"Wilder","year":"2016","journal-title":"Hepatology"},{"key":"R6-17-20210309","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jnma.2015.12.004","article-title":"A systematic review of race and ethnicity in hepatitis C clinical trial enrollment.","volume":"108","author":"Wilder","year":"2016","journal-title":"J Natl Med Assoc"},{"key":"R7-17-20210309","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"R8-17-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial.","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"R9-17-20210309","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"R10-17-20210309","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.","volume":"63","author":"Forns","year":"2015","journal-title":"J Hepatol"},{"key":"R11-17-20210309","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","article-title":"Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"R12-17-20210309","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","article-title":"Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIVhepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"key":"R18-17-20210309","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial.","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"R21-17-20210309","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/civ722","article-title":"Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE.","volume":"62","author":"Buti","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R22-17-20210309","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of alloral antiviral regimens in 996 human immunodeficiency virushepatitis C virus genotype 1-coinfected patients treated in routine practice.","volume":"64","author":"Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R23-17-20210309","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3117","article-title":"Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients.","volume":"22","author":"Backus","year":"2016","journal-title":"Antivir Ther"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0053-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/00000434-201806000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:22:28Z","timestamp":1786548148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201806000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/s41395-018-0053-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733114566.793545422","asserted-by":"object"}]},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}